Important: Dihexa has no completed human clinical trials. Core mechanism papers attributing its cognitive effects to HGF/c-Met pathway activation have been retracted or are under reproducibility scrutiny. Claims about its mechanism of action should not be stated as settled fact. All evidence is from animal models.
Overview
Dihexa (PNB-0408) is a small molecule peptidomimetic derived from angiotensin IV, developed by researchers at Washington State University. It is one of the most potent pro-cognitive compounds identified in preclinical research, with reported activity approximately 7 orders of magnitude (10 million times) more potent than BDNF in promoting synaptogenesis in hippocampal cell culture models. The proposed mechanism centers on the hepatocyte growth factor (HGF) / c-Met signaling pathway. Important note: some foundational mechanism papers attributing Dihexa's cognitive effects to HGF/c-Met pathway activation have been retracted or face reproducibility concerns. Dihexa has no completed human clinical trials. All evidence is from animal models.
Mechanism of Action
Dihexa is proposed to act as a potentiator of hepatocyte growth factor (HGF) binding to its receptor c-Met, a receptor tyrosine kinase expressed on neurons throughout the brain. The proposed downstream pathways include PI3K/Akt (neuronal survival), MAPK/ERK (cell proliferation), and Rac1/Cdc42 (actin cytoskeleton remodeling for synaptogenesis). Critical caveat: Some foundational mechanism papers attributing Dihexa's cognitive effects to HGF/c-Met pathway activation have been retracted or face reproducibility concerns. The HGF/c-Met pathway as the primary mechanism of cognitive enhancement is not established. McCoy et al. (2013) at Washington State University demonstrated preclinical cog
Research Evidence
- ~10 million times more potent than BDNF in promoting synaptogenesis in hippocampal cultures (McCoy et al., 2013)
- Reverses cognitive deficits in aged rats and scopolamine-induced amnesia models
- Proposed HGF/c-Met signaling mechanism (some foundational papers retracted; mechanism not established)
- Promotes hippocampal neurogenesis in the dentate gyrus
- Oral bioavailability and blood-brain barrier penetration due to N-hexanoyl modification
Bottom line: Dihexa is a preclinical research compound with no completed human clinical trials. Some foundational mechanism papers have been retracted. The animal model data is intriguing but has not been independently replicated in humans. It should be treated as early-stage preclinical research only.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for Dihexa are detailed in the full compound profile. See also: Dosage guide for Dihexa.
Sourcing & Quality
Dihexa is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Dihexa at Purgo Labs.